SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J Am Med Assoc 1995; 273: 28994
  • 2
    Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. J Am Med Assoc 1996; 276: 130915
  • 3
    Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol. Austria Urol 2001; 58: 41724
  • 4
    Efstathiou JA, Chen MH, Catalona WJ et al. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 2006; 68: 3427
  • 5
    Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin 2004; 54: 4152
  • 6
    American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 2000; 14: 778
  • 7
    Mohler J, Bahnson RR, Boston B et al. National Comprehensive Cancer Network. Practice Guidelines in Oncology, Prostate Cancer. 2007. Available at http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf
  • 8
    US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 143: 18591
  • 9
    American College of Physicians. Screening for prostate cancer. Ann Intern Med 1997; 126: 4804
  • 10
    Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death. first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 8391
  • 11
    Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994; 152: 19059
  • 12
    Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21: 273S309S
  • 13
    Schroder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 1999; 35: 53943
  • 14
    Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996; 3: 97104
  • 15
    Andriole GL, Levin DL, Crawford ED et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 4338
  • 16
    American Joint Committee on Cancer, American Cancer Society and American College of Surgeons. AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lippincott-Raven, 1997
  • 17
    Postma R, Schroder FH, Van Leenders G et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam a comparison of two rounds of screening. Eur Urol 2007; 52: 8997
  • 18
    Makinen T, Tammela T, Stenman U et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Can Res 2004; 10: 22316
  • 19
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl C. Results of a randomized, population –based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100: 1397405